StockpollyBeta
Get App
Delisting riskPopularity #5,422
PRPH · NASDAQ · Medical - Pharmaceuticals

ProPhase Labs (PRPH)

Operator of whole-genome sequencing, esophageal diagnostics, and OTC supplement brands.

$0.0100
vs last close+0.00 (+11.11%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue83423−2111101
Cost of revenue67433−3111101
Gross profit2−30001110000
9887815455633
Research & development000000000000
8887815455633
General & administrative8887815455633
Other expenses000000000000
Operating income−6−11−8−8−8−15−4−4−5−6−3−3
00−1−1−1−1−10−2−2−10
Interest income000000000000
Interest expense001111112411
Other non-operating income000000011−210
Income before tax−7−12−9−8−9−16−5−4−7−8−4−3
Income tax expense−2−3−3−2−315010−110
Net income from continuing operations−5−9−6−6−7−31−5−4−7−7−5−3
Discontinued operations000000900000
Other adjustments00000−4000000
Net income−5−9−6−6−7−344−4−7−7−5−3
EPS, basic−$3.00−$4.80−$3.50−$3.30−$3.50−$15.80$2.10−$1.10−$1.60−$0.87−$0.43−$0.22
EPS, diluted−$3.00−$4.80−$3.50−$3.30−$3.50−$15.80$2.10−$1.10−$1.60−$0.87−$0.43−$0.22
Weighted average shares, basic22222224481214
Weighted average shares, diluted22222224481214
EBITDA−5−9−7−6−5−14−3−4−41−2−2
Depreciation & amortization222231211511
EBIT−7−11−8−8−8−15−4−5−5−4−3−3